These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. LeMaistre CF; Craig FE; Meneghetti C; McMullin B; Parker K; Reuben J; Boldt DH; Rosenblum M; Woodworth T Cancer Res; 1993 Sep; 53(17):3930-4. PubMed ID: 8358720 [TBL] [Abstract][Full Text] [Related]
7. The induction and suppression of in vitro IgG anti-tetanus toxoid antibody synthesis by human lymphocytes stimulated with tetanus toxoid in the absence of in vivo booster immunizations. Lum LG; Culbertson NJ J Immunol; 1985 Jul; 135(1):185-91. PubMed ID: 2582031 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2. Zhang L; Waters C; Nichols J; Crumpacker C J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329 [TBL] [Abstract][Full Text] [Related]
10. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis. Bacha P; Forte SE; Perper SJ; Trentham DE; Nichols JC Eur J Immunol; 1992 Jul; 22(7):1673-9. PubMed ID: 1623918 [TBL] [Abstract][Full Text] [Related]
11. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Walz G; Zanker B; Brand K; Waters C; Genbauffe F; Zeldis JB; Murphy JR; Strom TB Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9485-8. PubMed ID: 2594781 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes. Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models. Bacha P; Forte S; Kassam N; Thomas J; Akiyoshi D; Waters C; Nichols J; Rosenblum M Cancer Chemother Pharmacol; 1990; 26(6):409-14. PubMed ID: 2225311 [TBL] [Abstract][Full Text] [Related]